Barclays upgraded shares of Novo Nordisk A/S (NYSE:NVO) from an underweight rating to an equal weight rating in a report issued on Tuesday morning, Benzinga reports. Barclays currently has $51.85 target price on the stock.
Several other research analysts also recently commented on NVO. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a buy rating to a hold rating in a research note on Wednesday, February 13th. Credit Suisse Group raised shares of Novo Nordisk A/S from a neutral rating to an outperform rating in a research note on Monday, April 29th. Finally, Pareto Securities downgraded shares of Novo Nordisk A/S from a buy rating to a hold rating in a research note on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $52.15.
NVO stock opened at $50.96 on Tuesday. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $52.83. The company has a market cap of $125.49 billion, a price-to-earnings ratio of 20.22, a price-to-earnings-growth ratio of 2.36 and a beta of 0.58.
Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Friday, May 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04. Novo Nordisk A/S had a net margin of 33.60% and a return on equity of 78.28%. The company had revenue of $4.46 billion for the quarter, compared to the consensus estimate of $4.35 billion. On average, analysts anticipate that Novo Nordisk A/S will post 2.45 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. TCG Advisors LP purchased a new position in Novo Nordisk A/S during the 1st quarter valued at $27,000. Camarda Financial Advisors LLC purchased a new position in Novo Nordisk A/S during the 1st quarter valued at $28,000. Premia Global Advisors LLC purchased a new position in Novo Nordisk A/S during the 1st quarter valued at $28,000. Bruderman Asset Management LLC purchased a new position in Novo Nordisk A/S during the 4th quarter valued at $29,000. Finally, Harvest Group Wealth Management LLC purchased a new position in Novo Nordisk A/S during the 1st quarter valued at $29,000. 7.15% of the stock is currently owned by institutional investors.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Read More: Bollinger Bands
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.